Phase II Study of 2-Methoxyestradiol NanoCrystal® Dispersion (2ME2) Alone and in Combination with Sunitinib (SU) in Patients with Metastatic Renal Cell Carcinoma (mRCC) Progressing on SU
Publication
, Conference
Harrison, MR; Pili, R; Logan, T; Wilding, G; Eickhoff, J; Sidor, C; Staab, MJ; Arnott, J; Liu, G
Duke Scholars
Location
Orlando, FL
Conference Name
ASCO 2009 Genitourinary Cancers Symposium
Citation
APA
Chicago
ICMJE
MLA
NLM
Harrison, M. R., Pili, R., Logan, T., Wilding, G., Eickhoff, J., Sidor, C., … Liu, G. (n.d.). Phase II Study of 2-Methoxyestradiol NanoCrystal® Dispersion (2ME2) Alone and in Combination with Sunitinib (SU) in Patients with Metastatic Renal Cell Carcinoma (mRCC) Progressing on SU. Presented at the ASCO 2009 Genitourinary Cancers Symposium, Orlando, FL.
Harrison, M. R., R. Pili, T. Logan, G. Wilding, J. Eickhoff, C. Sidor, M. J. Staab, J. Arnott, and G. Liu. “Phase II Study of 2-Methoxyestradiol NanoCrystal® Dispersion (2ME2) Alone and in Combination with Sunitinib (SU) in Patients with Metastatic Renal Cell Carcinoma (mRCC) Progressing on SU,” n.d.
Harrison MR, Pili R, Logan T, Wilding G, Eickhoff J, Sidor C, et al. Phase II Study of 2-Methoxyestradiol NanoCrystal® Dispersion (2ME2) Alone and in Combination with Sunitinib (SU) in Patients with Metastatic Renal Cell Carcinoma (mRCC) Progressing on SU. In.
Harrison MR, Pili R, Logan T, Wilding G, Eickhoff J, Sidor C, Staab MJ, Arnott J, Liu G. Phase II Study of 2-Methoxyestradiol NanoCrystal® Dispersion (2ME2) Alone and in Combination with Sunitinib (SU) in Patients with Metastatic Renal Cell Carcinoma (mRCC) Progressing on SU.
Location
Orlando, FL
Conference Name
ASCO 2009 Genitourinary Cancers Symposium